Edition:
India

Miragen Therapeutics Inc (MGEN.OQ)

MGEN.OQ on NASDAQ Stock Exchange Capital Market

7.55USD
13 Dec 2017
Change (% chg)

-- (--)
Prev Close
$7.55
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
26,151
52-wk High
$17.83
52-wk Low
$4.65

Chart for

About

Miragen Therapeutics, Inc., formerly Signal Genetics, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its clinical product... (more)

Overall

Beta: 1.97
Market Cap(Mil.): $202.81
Shares Outstanding(Mil.): 21.48
Dividend: --
Yield (%): --

Financials

BRIEF-Miragen Therapeutics reports third quarter financial results

* Miragen Therapeutics reports third quarter 2017 financial results and provides corporate update

09 Nov 2017

BRIEF-Miragen Therapeutics presents new data suggesting positive impact from systemically administered MRG-106

* Miragen Therapeutics presents new clinical data suggesting positive impact from systemically administered MRG-106 on mycosis fungoides form of cutaneous T-cell lymphoma at EORTC global task force meeting

13 Oct 2017

BRIEF-Miragen Therapeutics presents new MRG-201 preclinical data

* Miragen Therapeutics presents new MRG-201 preclinical data for Inhaled Microrna-29 Mimic Targeting Pulmonary Fibrosis Source text for Eikon: Further company coverage:

12 Sep 2017

BRIEF-Miragen Therapeutics Q2 loss per share $0.34

* Miragen Therapeutics reports second quarter 2017 financial results and provides corporate update

12 Aug 2017

Earnings vs. Estimates